252 related articles for article (PubMed ID: 26004083)
1. BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential.
Severson TM; Peeters J; Majewski I; Michaut M; Bosma A; Schouten PC; Chin SF; Pereira B; Goldgraben MA; Bismeijer T; Kluin RJ; Muris JJ; Jirström K; Kerkhoven RM; Wessels L; Caldas C; Bernards R; Simon IM; Linn S
Mol Oncol; 2015 Oct; 9(8):1528-38. PubMed ID: 26004083
[TBL] [Abstract][Full Text] [Related]
2. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
[TBL] [Abstract][Full Text] [Related]
3. Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E; van Tinteren H; Li Z; Raab S; Meul C; Avril S; Laddach N; Aubele M; Propping C; Gkazepis A; Schmitt M; Meindl A; Nederlof PM; Kiechle M; Lips EH
BMC Cancer; 2016 Oct; 16(1):811. PubMed ID: 27756336
[TBL] [Abstract][Full Text] [Related]
4. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
5. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
6. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
7. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
[TBL] [Abstract][Full Text] [Related]
8. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Brianese RC; Nakamura KDM; Almeida FGDSR; Ramalho RF; Barros BDF; Ferreira ENE; Formiga MNDC; de Andrade VP; de Lima VCC; Carraro DM
Breast Cancer Res Treat; 2018 Feb; 167(3):803-814. PubMed ID: 29116469
[TBL] [Abstract][Full Text] [Related]
10. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive molecular comparison of BRCA1 hypermethylated and BRCA1 mutated triple negative breast cancers.
Glodzik D; Bosch A; Hartman J; Aine M; Vallon-Christersson J; Reuterswärd C; Karlsson A; Mitra S; Niméus E; Holm K; Häkkinen J; Hegardt C; Saal LH; Larsson C; Malmberg M; Rydén L; Ehinger A; Loman N; Kvist A; Ehrencrona H; Nik-Zainal S; Borg Å; Staaf J
Nat Commun; 2020 Jul; 11(1):3747. PubMed ID: 32719340
[TBL] [Abstract][Full Text] [Related]
12. Mutations of TP53 and genes related to homologous recombination repair in breast cancer with germline BRCA1/2 mutations.
Kim J; Jeong K; Jun H; Kim K; Bae JM; Song MG; Yi H; Park S; Woo GU; Lee DW; Kim TY; Lee KH; Im SA
Hum Genomics; 2023 Jan; 17(1):2. PubMed ID: 36604691
[TBL] [Abstract][Full Text] [Related]
13. BRCA1/2-negative hereditary triple-negative breast cancers exhibit BRCAness.
Domagala P; Hybiak J; Cybulski C; Lubinski J
Int J Cancer; 2017 Apr; 140(7):1545-1550. PubMed ID: 27943282
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Tutt A; Tovey H; Cheang MCU; Kernaghan S; Kilburn L; Gazinska P; Owen J; Abraham J; Barrett S; Barrett-Lee P; Brown R; Chan S; Dowsett M; Flanagan JM; Fox L; Grigoriadis A; Gutin A; Harper-Wynne C; Hatton MQ; Hoadley KA; Parikh J; Parker P; Perou CM; Roylance R; Shah V; Shaw A; Smith IE; Timms KM; Wardley AM; Wilson G; Gillett C; Lanchbury JS; Ashworth A; Rahman N; Harries M; Ellis P; Pinder SE; Bliss JM
Nat Med; 2018 May; 24(5):628-637. PubMed ID: 29713086
[TBL] [Abstract][Full Text] [Related]
16. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
17. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
[TBL] [Abstract][Full Text] [Related]
18. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers.
Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S
BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626
[TBL] [Abstract][Full Text] [Related]
19. MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency.
Ren J; Jin F; Yu Z; Zhao L; Wang L; Bai X; Zhao H; Yao W; Mi X; Wang E; Olopade OI; Wei M
Tumour Biol; 2013 Dec; 34(6):3945-58. PubMed ID: 23860775
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Domagala P; Jakubowska A; Jaworska-Bieniek K; Kaczmarek K; Durda K; Kurlapska A; Cybulski C; Lubinski J
PLoS One; 2015; 10(6):e0130393. PubMed ID: 26083025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
